Department of Surgery and Colorectal Surgery, Maastricht University Medical Centre+, Maastricht, The Netherlands.
Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.
Tech Coloproctol. 2021 Jul;25(7):761-830. doi: 10.1007/s10151-021-02452-5. Epub 2021 May 8.
Treatment for cryptoglandular anal fistula (AF) is challenging and a lack of uniform outcomes in the literature prevents direct comparison of treatments. This can be addressed by developing a core outcome set, a standardised set of outcomes reported in all interventional studies for a specific condition. The aim of this systematic review is to assess the range of outcomes, their definitions, and the measurement instruments currently utilised in interventional studies for adult patients with AF. This will inform the development of an AF core outcome set.
Medline, Embase and The Cochrane Library were searched to identify all patient- and clinician-reported outcomes in studies assessing medical, surgical or combination treatment of adult patients with AF published from January 2008 to May 2020. The resulting outcomes were categorized according to the Core Outcome Measurement in Effectiveness Trials (COMET) taxonomy to better understand their distribution.
In total, 155 studies were included, 552 outcomes were extracted, with a median of three outcomes (interquartile range 2-5) per study. Only 25% of studies demonstrated high-quality outcome reporting. The outcomes were merged into 52 unique outcomes and structured into four core areas and 14 domains, with the majority in the domain of physiological or clinical (gastrointestinal) outcomes. The most commonly reported outcomes were healing (77%), incontinence (63%), and recurrence (40%), with no single outcome assessed across all studies. There was a wide variation in outcome definitions and measurement instruments used.
There is substantial heterogeneity in outcomes, definitions, and measurement instruments reported in interventional studies for cryptoglandular anal fistula. This emphasises the need for standardised outcome reporting and measurement.
肛门腺源性肛瘘(AF)的治疗具有挑战性,文献中缺乏统一的结果导致无法直接比较治疗方法。通过制定核心结局集可以解决这个问题,这是一种标准化的结局集合,用于报告特定疾病的所有干预性研究。本系统评价的目的是评估目前用于治疗成人 AF 的干预性研究中所使用的结局范围、定义和测量工具,这将为 AF 核心结局集的制定提供信息。
检索 Medline、Embase 和 The Cochrane Library,以确定 2008 年 1 月至 2020 年 5 月期间发表的评估成人 AF 患者的医学、手术或联合治疗的研究中患者和临床医生报告的所有结局。根据有效性试验核心结局测量(COMET)分类法对这些结局进行分类,以便更好地了解其分布情况。
共纳入 155 项研究,提取了 552 个结局,每个研究的中位数为 3 个结局(四分位距 2-5)。只有 25%的研究表现出高质量的结局报告。将结局合并为 52 个独特的结局,并分为四个核心领域和 14 个域,其中大多数属于生理或临床(胃肠道)结局。报告最多的结局是愈合(77%)、失禁(63%)和复发(40%),但没有一个结局在所有研究中都得到评估。结局的定义和使用的测量工具差异很大。
肛门腺源性肛瘘的干预性研究中报告的结局、定义和测量工具存在很大的异质性。这强调了标准化结局报告和测量的必要性。